Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…
INTERVIEW
With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
Gilead Sciences is embarking on a new journey in the Japanese market after winding up its long-term partnership with Japan Tobacco to bring back its “missing pillar” in the country - HIV. The company’s Japan helmsman Luc Hermans sat with…
To read the full story
INTERVIEW
- As Election Campaign Begins, LDP’s Eto Says Debate Needed to Possibly Expand 2% Adjustment Rate for Drug Price Revisions
July 4, 2019
- As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
- Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
- Nichi-Iko to Leverage Synergies of Integration with Elmed Eisai: Sales Head
April 22, 2019
- With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…